Let's look at a case study of similar company as Noxopharm.
Snapshot:
Imugene has 6.42 Billion shares with a market cap of $770 million, Noxopharm only has 292 million shares, so who is still concerned about raising funds at this SP ?
Imugene Limited (IMU) is an Australian immuno-oncology focused Biopharmaceutical Company developing range of new and novel immune therapies that seek to activate the immune system of cancer patients to treat and eradicate tumours. The products under development by the group are HER-Vaxx, PD1-Vaxx (formerly KEY-Vaxx), CF-33 and B-Vax.
Let's look at a case study of similar company as...
Add NOX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
7.9¢ |
Change
-0.001(1.25%) |
Mkt cap ! $23.08M | |||
| Open | High | Low | Value | Volume |
| 8.0¢ | 8.0¢ | 7.6¢ | $11.76K | 150.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 119201 | 8.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 9.0¢ | 21000 | 2 |
View Market Depth
| Last trade - 15.56pm 03/06/2024 (20 minute delay) ? |
|
|||||
|
Last
7.8¢ |
Change
-0.001 ( 1.27 %) |
||||
| Open | High | Low | Volume | ||
| 7.9¢ | 7.9¢ | 7.8¢ | 72652 | ||
| Last updated 11.12am 03/06/2024 ? | |||||
| NOX (ASX) Chart |